Dianthus Therapeutics, Inc. (NASDAQ:DNTH) Receives Average Recommendation of “Buy” from Brokerages

Shares of Dianthus Therapeutics, Inc. (NASDAQ:DNTH) have earned an average recommendation of “Buy” from the fourteen analysts that are presently covering the stock, Marketbeat.com reports. One investment analyst has rated the stock with a sell recommendation, eleven have given a buy recommendation and two have issued a strong buy recommendation on the company. The average twelve-month target price among brokerages that have issued a report on the stock in the last year is $117.8182.

Several research firms have recently weighed in on DNTH. Truist Financial increased their price target on shares of Dianthus Therapeutics from $63.00 to $110.00 and gave the company a “buy” rating in a research note on Monday, March 9th. Wells Fargo & Company initiated coverage on shares of Dianthus Therapeutics in a report on Thursday, March 19th. They set an “overweight” rating and a $135.00 target price on the stock. HC Wainwright increased their target price on shares of Dianthus Therapeutics from $47.00 to $130.00 and gave the stock a “buy” rating in a report on Monday, March 9th. William Blair reiterated an “outperform” rating on shares of Dianthus Therapeutics in a report on Monday, March 16th. Finally, Oppenheimer increased their target price on shares of Dianthus Therapeutics to $145.00 and gave the stock an “outperform” rating in a report on Monday, March 9th.

Dianthus Therapeutics Stock Performance

Dianthus Therapeutics stock opened at $84.57 on Friday. The stock’s 50 day simple moving average is $87.36 and its two-hundred day simple moving average is $64.45. The stock has a market cap of $4.62 billion, a price-to-earnings ratio of -20.48 and a beta of 1.18. Dianthus Therapeutics has a fifty-two week low of $16.64 and a fifty-two week high of $96.50.

Dianthus Therapeutics (NASDAQ:DNTH) last issued its quarterly earnings results on Tuesday, May 5th. The company reported ($0.85) EPS for the quarter, topping analysts’ consensus estimates of ($1.07) by $0.22. Dianthus Therapeutics had a negative return on equity of 27.30% and a negative net margin of 12,998.50%.The firm had revenue of $0.46 million for the quarter, compared to analysts’ expectations of $0.40 million. On average, analysts predict that Dianthus Therapeutics will post -3.82 earnings per share for the current year.

Insider Activity

In other news, EVP Simrat Randhawa sold 26,530 shares of the firm’s stock in a transaction on Monday, June 1st. The shares were sold at an average price of $90.62, for a total value of $2,404,148.60. Following the sale, the executive vice president directly owned 4,000 shares in the company, valued at approximately $362,480. This trade represents a 86.90% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CAO Edward Carr sold 43,682 shares of Dianthus Therapeutics stock in a transaction dated Thursday, March 12th. The shares were sold at an average price of $81.49, for a total value of $3,559,646.18. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 349,551 shares of company stock valued at $28,968,156 over the last quarter. Company insiders own 3.02% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in DNTH. Fairmount Funds Management LLC increased its holdings in Dianthus Therapeutics by 22.2% in the third quarter. Fairmount Funds Management LLC now owns 3,307,191 shares of the company’s stock worth $130,138,000 after purchasing an additional 600,000 shares in the last quarter. Vestal Point Capital LP increased its holdings in shares of Dianthus Therapeutics by 88.2% in the 2nd quarter. Vestal Point Capital LP now owns 3,200,000 shares of the company’s stock worth $59,616,000 after purchasing an additional 1,499,931 shares in the last quarter. Wellington Management Group LLP increased its holdings in shares of Dianthus Therapeutics by 3,366.9% in the 3rd quarter. Wellington Management Group LLP now owns 2,577,662 shares of the company’s stock worth $101,431,000 after purchasing an additional 2,503,311 shares in the last quarter. Vanguard Group Inc. increased its holdings in shares of Dianthus Therapeutics by 24.7% in the 4th quarter. Vanguard Group Inc. now owns 2,048,452 shares of the company’s stock worth $84,417,000 after purchasing an additional 406,254 shares in the last quarter. Finally, TCG Crossover Management LLC increased its holdings in shares of Dianthus Therapeutics by 11.7% in the 3rd quarter. TCG Crossover Management LLC now owns 1,676,624 shares of the company’s stock worth $65,975,000 after purchasing an additional 175,000 shares in the last quarter. 47.53% of the stock is owned by institutional investors.

Dianthus Therapeutics Company Profile

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc was founded in 2019 and is headquartered in New York, New York.